Carsten Ehrhardt has established an international reputation in his area of expertise, “Inhalation Drug Delivery and Pulmonary Biopharmaceutics”. The aim of this field of scientific endeavour is to describe the behaviour of drug and biological molecules following their administration to the lung as inhaled aerosols. The field has become increasingly important over the last 20 years as the incidence of lung-related diseases and the morbidity due to these conditions is increasing a more than 5% per year. Assoc. Prof. Ehrhardt's research is primarily preclinical using both cell and animal models, which allows a wide array of discovery and development works. In this context, his laboratory has been credited with pioneering work on the development of primary cultures of human alveolar epithelial cells. The technical expertise of the laboratory ranges from pharmaceutics to pharmacokinetics, pharmacology, physiology, cell & molecular biology to pathology and immunocytochemistry. Recently, we started multidisciplinary, translational investigations into the role that drug transporters play in the pathogenesis of tobacco-related chronic obstructive pulmonary disease (COPD). The unique combination of cell physiological basis and pharmaceutical application has led to numerous research collaborations, nationally and internationally, as well as to a continuous stream of visitors to my laboratory.
Novo Nordisk A/S, Sepracor Inc., Enterprise Ireland, Rovi Cosmetics, Pfizer Inc., IRCSET, SFI Strategic Research Cluster (07/SRC/B1154), Infectious Diseases Research Institute, Chiesi Farmaceutici S.p.A., University of Sydney, Flight Attendant Medical Research Institute, Ministerio da Educacao, Coordenacao de Aperfeicoamento de Pessoal de Nível Superior (CAPES) Foundation, Iraqi Ministry of High Education and Scientific Research (MOHESR), COST Actions BM1201 and MP1404.